Biocon Q1 Revenue Hits Rs 39.4 Billion, Up 15 Per Cent

08 Aug 2025 CW Team

Core EBITDA stood at Rs 10 billion with a 25 per cent margin, supported by strong performances across business segments.

Segment Highlights:

Biosimilars: Revenue reached Rs 24.6 billion, up 18 per cent YoY. EBITDA rose 36 per cent to Rs 6.45 billion, with a margin of 26 per cent.
Generics: Revenue stood at Rs 6.97 billion, up 6 per cent YoY, driven by new product launches in the US and Europe.
CRDMO (Syngene): Revenue rose 11 per cent YoY to Rs 8.75 billion. EBITDA reached Rs 2.24 billion.

Biocon’s net R&D investment was Rs 2.05 billion, amounting to 7 per cent of revenue (excluding Syngene).

Leadership Commentary:

Kiran Mazumdar-Shaw, Chairperson, stated that Biocon entered FY26 with strong momentum, particularly in biosimilars and CRDMO, adding that recent US FDA approvals and launches in Canada and Europe strengthen Biocon’s global footprint.

Siddharth Mittal, CEO of Biocon Limited, noted that generics growth was driven by the successful launch of products such as Liraglutide in the EU and Dasatinib in the US.

Shreehas Tambe, CEO of Biocon Biologics, confirmed a strong 18 per cent growth in biosimilars revenue, highlighting approvals for biosimilars including Kirsty™ (Insulin Aspart) and Yesafili™ (Aflibercept).

Peter Bains, CEO of Syngene, attributed the 11 per cent rise in CRDMO revenue to successful transitions of pilot projects to long-term contracts.

Corporate Developments:

Biocon raised Rs 45 billion via a Qualified Institutional Placement (QIP) in June 2025 to increase its stake in Biocon Biologics and provide exits for equity investors.

Sustainability Achievements:

Biocon received a gold rating from EcoVadis, placing it in the top 5 per cent globally for sustainability. Syngene was ranked India’s most sustainable pharma/biotech firm by TIME and Statista.

Regulatory Milestones:

Biocon’s API sites in Visakhapatnam and Bengaluru passed Brazil’s ANVISA audits with zero observations. Its Bengaluru facility was also inspected by the Malta Medicines Authority.

Outlook:

With expanded manufacturing capacity and continued innovation, Biocon is confident of long-term growth across biosimilars, generics, and CRDMO, further supporting its mission of affordable access to complex therapies worldwide.

Biocon Limited, a global innovation-driven biopharmaceutical company, reported a consolidated operating revenue of Rs 39.4 billion for the quarter ended 30 June 2025 (Q1 FY26), marking a 15 per cent increase year-on-year. On a like-for-like basis, excluding the divestment gain from the previous year, EBITDA rose 19 per cent to Rs 8.3 billion, while Profit Before Tax (before exceptional items) increased 72 per cent to Rs 970 million.Core EBITDA stood at Rs 10 billion with a 25 per cent margin, supported by strong performances across business segments.Segment Highlights:Biosimilars: Revenue reached Rs 24.6 billion, up 18 per cent YoY. EBITDA rose 36 per cent to Rs 6.45 billion, with a margin of 26 per cent.Generics: Revenue stood at Rs 6.97 billion, up 6 per cent YoY, driven by new product launches in the US and Europe.CRDMO (Syngene): Revenue rose 11 per cent YoY to Rs 8.75 billion. EBITDA reached Rs 2.24 billion.Biocon’s net R&D investment was Rs 2.05 billion, amounting to 7 per cent of revenue (excluding Syngene).Leadership Commentary:Kiran Mazumdar-Shaw, Chairperson, stated that Biocon entered FY26 with strong momentum, particularly in biosimilars and CRDMO, adding that recent US FDA approvals and launches in Canada and Europe strengthen Biocon’s global footprint.Siddharth Mittal, CEO of Biocon Limited, noted that generics growth was driven by the successful launch of products such as Liraglutide in the EU and Dasatinib in the US.Shreehas Tambe, CEO of Biocon Biologics, confirmed a strong 18 per cent growth in biosimilars revenue, highlighting approvals for biosimilars including Kirsty™ (Insulin Aspart) and Yesafili™ (Aflibercept).Peter Bains, CEO of Syngene, attributed the 11 per cent rise in CRDMO revenue to successful transitions of pilot projects to long-term contracts.Corporate Developments:Biocon raised Rs 45 billion via a Qualified Institutional Placement (QIP) in June 2025 to increase its stake in Biocon Biologics and provide exits for equity investors.Sustainability Achievements:Biocon received a gold rating from EcoVadis, placing it in the top 5 per cent globally for sustainability. Syngene was ranked India’s most sustainable pharma/biotech firm by TIME and Statista.Regulatory Milestones:Biocon’s API sites in Visakhapatnam and Bengaluru passed Brazil’s ANVISA audits with zero observations. Its Bengaluru facility was also inspected by the Malta Medicines Authority.Outlook:With expanded manufacturing capacity and continued innovation, Biocon is confident of long-term growth across biosimilars, generics, and CRDMO, further supporting its mission of affordable access to complex therapies worldwide.

Infrastructure Urban

10 Mar 2026

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Equipment

10 Mar 2026

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Equipment

10 Mar 2026

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..